Clinical Pathway Discloses One Surgeon's $425 Habit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

PHILADELPHIA--When practice guidelines or pathways take financial considerations into account, they may be termed clinical financial pathways (CFPs). This technique was developed by Kent Giles, MPPM, vice president of development at PhyMatrix, a physician management company headquartered in West Palm Beach, Fla, and is currently being utilized by PhyMatrix to reduce unnecessary medical costs.

PHILADELPHIA--When practice guidelines or pathways take financialconsiderations into account, they may be termed clinical financialpathways (CFPs). This technique was developed by Kent Giles, MPPM,vice president of development at PhyMatrix, a physician managementcompany headquartered in West Palm Beach, Fla, and is currentlybeing utilized by PhyMatrix to reduce unnecessary medical costs.

Developing CFPs involves seven steps, Mr. Giles said at the Associationof Cancer Executives meeting (see also page 20): Select a diseaseprocess, form a knowledgeable team, clarify the current stateof medical knowledge, develop the pathway, assign costs to eachprocess, implement the pathway, and monitor the results.

During development of the prostate CFP, he said, the team foundthat one urologist was using three surgical trays per radicalprostatectomy to access the three instruments he needed, sincethe hospital routinely placed only one of these instruments onthe surgical tray.

This practice, which added $425 in unnecessary costs for extrasterilization and wasted anesthesiologist and surgeon time, waseliminated with implementation of the CFP, and the patient's timeunder anesthesia was reduced by 30 minutes, ie, a quality enhancement.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.